MTHFR and cerebrovascular disorder: A meta-regression analysis of randomized trials (RCTs) of folic acid for a reduction in the risk of cardio-/cerebrovascular disease (CVD) [69] indicated that the intervention reduced the risk of CVD in people with lower baseline tHcy (e.g., ≤10 μmol/L) (among whom the prevalence of MTHFR 677C>T wild-type subjects might be reasonably assumed), whereas in those with higher baseline tHcy (prevalence of variant carriers is reasonable to assume) there was no benefit or even harm was suggested [69].